Roche Sets Hemophilia Drug Price at $482,000 After Approval

Roche Holding AG’s Hemlibra hemophilia treatment won approval from U.S. regulators, giving the Swiss behemoth a foothold in the $10 billion global market for treating blood disorders.

The drug, also known as emicizumab, was cleared for use by some patients who have fewer treatment options and are at greater risk of life-threatening bleeds. The therapy’s wholesale acquisition price was set at $482,000 for the first year of treatment and then about $448,000 a year for a patient weighing 58 kilograms (128 pounds), Basel, Switzerland-based Roche said in a statement Nov. 16.

The compound could be key in letting Roche, the ...